Open AccessEffect of anti-tuberculosis therapy on polymorphic drug metabolizing enzyme CYP2C9 using phenytoin as a probe drug
Author(s) -
Melvin George,
Deepak Gopal Shewade,
Senthil Kumar,
Adithan Chandrasekaran
Publication year - 2012
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.99314
Subject(s) - cyp2c9 , phenytoin , pharmacology , rifampicin , cyp2d6 , isoniazid , metabolite , medicine , therapeutic drug monitoring , genotyping , drug , chemistry , genotype , tuberculosis , cytochrome p450 , biochemistry , metabolism , epilepsy , pathology , psychiatry , gene
Patients on anti-tuberculosis therapy (ATT) are more prone to drug interactions in the presence of coexisting illnesses which warrant drug therapy. Rifampicin is a strong CYP enzyme inducer while isoniazid is a potent CYP inhibitor. The objective of the study was to find the net effect of one month ATT on CYP2C9 enzyme and to correlate it with respect to the CYP2C9 genetic polymorphisms.